RI S2851

Licensed pharmacists may independently test for and treat influenza, COVID-19, strep throat, and post-exposure prophylaxis for sexually transmitted infections using CLIA-waived tests under statewide protocols adopted by the Board of Pharmacy.

Pharmacists must complete disease-specific education and training requirements before providing test-and-treat services, with the Board authorized to require ongoing continuing education.

Patient encounters must be documented, and pharmacists must notify the patient's primary care provider within 7 business days upon patient consent.

State-regulated health insurance plans, Medicaid, nonprofit hospital/medical service corporations, and HMOs must cover pharmacist test-and-treat services beginning January 1, 2027, with plans required to include pharmacists in their medical provider networks.

The Board of Pharmacy must promulgate implementing rules within 6 months of the act's effective date.